Date: Wednesday 17 September 2014 - Thursday 18 September 2014

Location: London, UK

ACI’s Cancer Drug Discovery & Preclinical Development conference takes place in London, UK on 17th & 18th September 2014. This keystone event will focus on the early stages of cancer drug research, with interactive debate and detailed presentations on a wide range of topics. A diverse line-up of academic and industry experts will be there to ensure fair and balanced coverage of the latest developments in the field. All this takes place in a friendly environment designed to encourage networking between attendees

Conference Agenda

Hear in-depth presentations on a range of key issues of interest to those working in early stage oncology research and development. Topics include:

  • Improving the Efficiency and Effectiveness of Cancer Drug Discovery
  • Building and Maintaining Industry-Academia Alliances in Oncology
  • Acquired Resistance to Targeted Kinase Inhibitors – Causes, Consequences & Solutions
  • Discovery of a Novel Inhibitor of mTOR Pathway in Clinical Development
  • Novel RNA Oligonucleotide that Inhibits Liver Carcinogenesis In Vivo
  • Using Preclinical Data to Inform Clinical Dose & Schedule in Cancer Drug Trials
  • Using Multi-Scale Modelling to Support Preclinical Developments
  • Preclinical Models for Drug Discovery & Translating Combination Approaches to Clinical Trials 

Why Attend?     


  • Meet experts from the world of early-stage cancer drug development
  • Analyse trends in drug discovery within both academia and industry
  • Explore the road from discovery to development to final approval
  • Learn about the latest computer-aided drug design technologies
  • Hear case histories on drug discovery and preclinical development 

Confirmed Speakers     


Tao You, Systems Biologist, AstraZeneca

Gary Wilkinson, DMPK Project Leader, Oncology iMed, AstraZeneca

Sean Kitson, Investigator of Radiochemistry, Almac Group

Aliki Taylor, Observational Research Director, Amgen

Graham Smith, Team Leader, PET Radiochemistry, The Institute for Cancer Research

Steven Whittaker, Team Leader, Career Development Faculty, The Institute for Cancer Research

Angela Kukula, Director of Enterprise, The Institute for Cancer Research

Tim Hammonds, Deputy Director of Discovery, Cancer Research Technology

Hazel Jones, Head of Combination Therapies, Cancer Research UK

José Alfón, Vice President, Research and Development, Ability Pharmaceuticals

Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics

Simon Cook, Group Leader, Signalling Laboratory, The Babraham Institute

Paul Finn, Professorial Research Fellow, University of Buckingham

Chandrasekhar Natarajan, Chief Scientific Officer, ViNa Pharma

Xavier Jacq, Head of Biology, MISSION Therapeutics

Eric Fernandez, Project Leader, Physiomics

Mike Nelson, Partner, HGF Limited

Arthur Alberts, Professor of Cancer & Cell Biology, Van Andel Institute

Who Should Attend?     

Research Scientists, Team Leaders, Heads, Managers, Directors and other professionals working in the following areas related to oncology:

  • Drug Discovery
  • Preclinical Development
  • Exploratory Development 
  • Medicinal Chemistry
  • Computational chemistry
  • Formulation
  • Targeted therapeutics
  • Translational Medicine
  • Personalised medicine
  • Genetics
  • Regulatory Affairs
  • Data Management


Claire Taylor-Payne

Tel: +44 (0) 203 141 0601


Sponsorship and Commercial Opportunities

Victor Kinlock

Tel: +44 (0)20 3141 0626


Speaking Opportunities:

Chris Taylor

Tel: +44 (0)20 3141 0602


Conference Venue

Mercure Hotel London Bridge

71-79 Southwark St, Bankside
London SE1 0JA


Media partners